2型糖尿病患者肌少性肥胖研究进展 ^*

Progress in sarcopenic obesity research among type 2 diabetes mellitus patients

摘要

2型糖尿病患者群体中, 肌少性肥胖的检出率逐年上升, 其发生机制涉及胰岛素抵抗与代谢性炎症的交互作用。明确该代谢综合征的病理机制是实施精准医疗、延缓机体功能衰退的核心前提。为此, 本文系统梳理了老年2型糖尿病并发肌少性肥胖的临床界定、诊断规范与评价体系, 重点探讨了两者的协同致病机制, 并进一步讨论了未来个性化干预与临床药物治疗的转化应用前景。

Abstract

In patients with type 2 diabetes mellitus (T2DM), the prevalence of sarcopenic obesity has been increasing annually, with its underlying mechanisms involving the interplay between insulin resistance and metabolic inflammation. Elucidating the pathophysiology of this metabolic syndrome is a core prerequisite for implementing precision medicine and delaying functional decline. To this end, this article systematically reviews the clinical definitions, diagnostic standards, and evaluation systems for sarcopenic obesity in elderly T2DM patients. It highlights the synergistic pathogenic mechanisms between the two conditions and further discusses the translational prospects for future personalized interventions and clinical pharmacological treatments.

关键词

2型糖尿病 / 肌少性肥胖 / 胰岛素抵抗 / 代谢性炎症

Key words

Type 2 diabetes mellitus / Sarcopenia obesity / Insulin resistance / Metabolic inflammation

参考文献

[1] Antar S A, Ashour N A, Sharaky M, et al. Diabetes mellitus: classification, mediators, and complications; a gate to identify potential targets for the development of new effective treatments[J]. Biomed Pharmacother, 2023, 168: 115734.

[2] Liu C, Wong P Y, Chung Y L, et al. Deciphering the “obesity paradox” in the elderly: a systematic review and meta—analysis of sarcopenic obesity[J]. Obes Rev, 2023, 24(2): e13534.

[3] Rosenberg I H, Roubenoff R . Stalking sarcopenia[J]. Ann Intern Med, 1995, 123(9): 727-728.

[4] Bai J, Zhang Y, He L, et al. Normal weight central obesity and its impact on type 2 diabetes mellitus[J]. Curr Diabetes Rep, 2024, 25(1): 3.

[5] Salom Vendrell C, García Tercero E, Moro Hernández J B, et al. Sarcopenia as a little—recognized comorbidity of typeⅡ diabetes mellitus: a review of the diagnosis and treatment[J]. Nutrients, 2023, 15(19): 4149.

[6] Donini L M, Busetto L, Bischoff S C, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement[J]. Obes Facts, 2022, 15(3): 321-335.

[7] Rosenberg I H . Sarcopenia: origins and clinical relevance[J]. Clin Geriatr Med, 2011, 27(3): 337-339.

[8] Newman A B, Kupelian V, Visser M, et al. Sarcopenia: alternative definitions and associations with lower extremity function[J]. J Am Geriatr Soc, 2003, 51(11): 1602-1609.

[9] Cruz—Jentoft A J, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(4): 601.

[10] Falcon L J, Harris—Love M O . Sarcopenia and the new ICD—10—CM code: screening, staging, and diagnosis considerations[J]. Fed Pract, 2017, 34(7): 24-32.

[11] Chen L K, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307,e2.

[12] Arroyo—Johnson C, Mincey K D . Obesity epidemiology worldwide[J]. Gastroenterol Clin N Am, 2016, 45(4): 571-579.

[13] Khor E Q, Lim J P, Tay L, et al. Obesity definitions in sarcopenic obesity: differences in prevalence, agreement and association with muscle function[J]. J Frailty Aging, 2020, 9(1): 37-43.

[14] Donini L M, Busetto L, Bischoff S C, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement[J]. Clin Nutr, 2022, 41(4): 990-1000.

[15] Park J E, Lee S, Kim K . The effect of combining nutrient intake and physical activity levels on central obesity, sarcopenia, and sarcopenic obesity: a population—based cross—sectional study in South Korea[J]. BMC Geriatr, 2023, 23(1): 119.

[16] Murdock D J, Wu N, Grimsby J S, et al. The prevalence of low muscle mass associated with obesity in the USA[J]. Skeletal Muscle, 2022, 12(1): 26.

[17] Gao Q, Mei F, Shang Y, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta—analysis[J]. Clin Nutr, 2021, 40(7): 4633-4641.

[18] Mo Y H, Yang C, Su Y D, et al. Prevalence and diagnostic agreement of sarcopenic obesity with different definitions among Chinese community—dwelling older adults[J]. Age Ageing, 2022, 51: afab272.

[19] Poznyak A, Grechko A V, Poggio P, et al. The diabetes mellitus—atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation[J]. Int J Mol Sci, 2020, 21(5): 1835.

[20] Rhea E M, Leclerc M, Yassine H N, et al. State of the science on brain insulin resistance and cognitive decline due to Alzheimer's disease[J]. Aging Dis, 2024, 15(4): 1688-1725.

[21] Izzo A, Massimino E, Riccardi G, et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors[J]. Nutrients, 2021, 13(1): 183.

[22] Sylow L, Tokarz V L, Richter E A, et al. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia[J]. Cell Metab, 2021, 33(4): 758-780.

[23] Landi F, Onder G, Bernabei R . Sarcopenia and diabetes: two sides of the same coin[J]. J Am Med Dir Assoc, 2013, 14(8): 540-541.

[24] Tan S, Gunendi Z, Meray J, et al. The evaluation of muscle strength and architecture in type 1 diabetes mellitus: a cross—sectional study[J]. BMC Endocr Disord, 2022, 22(1): 153.

[25] Seo J A, Kang M C, Yang W M, et al. Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity[J]. Nat Commun, 2020, 11: 2024.

[26] Just P A, Charawi S, Denis R G P, et al. Lkb1 suppresses amino acid—driven gluconeogenesis in the liver[J]. Nat Commun, 2020, 11: 6127.

[27] Jung U J . Sarcopenic obesity: involvement of oxidative stress and beneficial role of antioxidant flavonoids[J]. Antioxidants, 2023, 12(5): 1063.

[28] Ishibashi C, Nakanishi K, Nishida M, et al. Myostatin as a plausible biomarker for early stage of sarcopenic obesity[J]. Sci Rep, 2024, 14(1): 28629.

[29] Durack J, Lynch S V . The gut microbiome: relationships with disease and opportunities for therapy[J]. J Exp Med, 2019, 216(1): 20-40.

[30] Ticinesi A, Nouvenne A, Cerundolo N, et al. Gut microbiota, muscle mass and function in aging: a focus on physical frailty and sarcopenia[J]. Nutrients, 2019, 11(7): 1633.

[31] Lahiri S, Kim H, Garcia—Perez I, et al. The gut microbiota influences skeletal muscle mass and function in mice[J]. Sci Transl Med, 2019, 11(502): eaan5662.

[32] Ji Q, Chai S, Zhang R, et al. Prevalence and co—prevalence of comorbidities among Chinese adult patients with type 2 diabetes mellitus: a cross—sectional, multicenter, retrospective, observational study based on 3B study database[J]. Front Endocrinol, 2024, 15: 1362433.

[33] Nunan E, Wright C L, Semola O A, et al. Obesity as a premature aging phenotype — implications for sarcopenic obesity[J]. Geroscience, 2022, 44(3): 1393-1405.

[34] Wu H, Ballantyne C M . Metabolic inflammation and insulin resistance in obesity[J]. Circ Res, 2020, 126(11): 1549-1564.

[35] Ahmed B, Sultana R, Greene M W . Adipose tissue and insulin resistance in obese[J]. Biomed Pharmacother, 2021, 137: 111315.

[36] Li B, Leung J C K, Chan L Y Y, et al. A global perspective on the crosstalk between saturated fatty acids and Toll—like receptor 4 in the etiology of inflammation and insulin resistance[J]. Prog Lipid Res, 2020, 77: 101020.

[37] Seo J B, Riopel M, Cabrales P, et al. Knockdown of Ant2 reduces adipocyte hypoxia and improves insulin resistance in obesity[J]. Nat Metab, 2019, 1(1): 86-97.

[38] Conway J, Duggal N A . Ageing of the gut microbiome: potential influences on immune senescence and inflammageing[J]. Ageing Res Rev, 2021, 68: 101323.

[39] Mirzai S, Carbone S, Batsis J A, et al. Sarcopenic obesity and cardiovascular disease: an overlooked but high—risk syndrome[J]. Curr Obes Rep, 2024, 13(3): 532-544.

[40] He L, Su Z, Wang S . The anti—obesity effects of polyphenols: a comprehensive review of molecular mechanisms and signal pathways in regulating adipocytes[J]. Front Nutr, 2024, 11: 1393575.

[41] da Silva Mendes de Farias T, da Paixao R I, Cruz M M, et al. Melatonin supplementation attenuates the pro—inflammatory adipokines expression in visceral fat from obese mice induced by a high—fat diet[J]. Cells, 2019, 8(9): 1041.

[42] Kawai T, Autieri M V, Scalia R . Adipose tissue inflammation and metabolic dysfunction in obesity[J]. Am J Physiol Cell Physiol, 2021, 320(3): C375-C391.

[43] Ter Horst R, van den Munckhof I C L, Schraa K, et al. Sex—specific regulation of inflammation and metabolic syndrome in obesity[J]. Arterioscler Thromb Vasc Biol, 2020, 40(7): 1787-1800.

[44] Nay K, Jollet M, Goustard B, et al. Gut bacteria are critical for optimal muscle function: a potential link with glucose homeostasis[J]. Am J Physiol Endocrinol Metab, 2019, 317(1): E158-E171.

[45] de Groot P, Scheithauer T, Bakker G J, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time[J]. Gut, 2020, 69(3): 502-512.

[46] McKendry J, Currier B S, Lim C, et al. Nutritional supplements to support resistance exercise in countering the sarcopenia of aging[J]. Nutrients, 2020, 12(7): 2057.

[47] Bilski J, Pierzchalski P, Szczepanik M, et al. Multifactorial mechanism of sarcopenia and sarcopenic obesity. role of physical exercise, microbiota and myokines[J]. Cells, 2022, 11(1): 160.

[48] Prado C M, Batsis J A, Donini L M, et al. Sarcopenic obesity in older adults: a clinical overview[J]. Nat Rev Endocrinol, 2024, 20(5): 261-277.

基金资助

^*黑龙江省自然科学基金项目(LH2022H038)